{"entity":{"id":"nct06147570","kind":"trial","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of HS-10365 capsules in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06147570 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 62 participants planned, started 2023-09-25 and due to reach its primary completion in 2027-08-31. Interventions recorded: HS-10365 capsules.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06147570","url":"https://clinicaltrials.gov/study/NCT06147570"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06147570","phase":"2","setting":"A Phase II, Open-label, Multicenter Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HS-10365 as First-Line Treatment for Patients With Locally Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","enrolled":62,"outcomes":[]},"route":"/trials/nct06147570/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}